The members of Emergent Growth Fund II are currently reviewing applications for funding new companies.  Interested companies should submit their applications through our on-line application process.

Sensory Analytics developed automated coating measurement devices that uniquely solve the challenges of excess measurement times, destructive test methods and non-value added measurement and analysis man hours.

Grooveshark is a digital music company with the goal of bringing every song to everyone in the world on every device in the world. Their web service allows users to upload music and stream it for free across the web while giving people access to a subscription premium version of the service with access from your mobile device.

Protochips creates the world's most advanced specimen supports for electron microscopy, converting these instruments from cameras into complete nanomaterials laboratories. Protochips' products enable the highest resolution of nanostructures in their native environments and have proven themselves to be of enormous value in both Life Science and Materials Science applications all the way from R&D through product Q/A. PAN led the Series A round of investment, with participants including the Emergent Growth Fund, the Jefferson Corner Group, the Wilmington Investor Network and several individual investors.

Bit Cauldron Corporation is at the leading edge of a new multi-billion dollar industry, 3DTV. Bit Cauldron makes key 3D enabling technologies, starting with 3D eyeware, that are necessary for a great user experience. Bit Cauldron’s mission is to empower consumers to view, create, print, and share 3D content.

Optima Neuroscience is a biomedical technology company developing novel software, systems and devices for the diagnosis and treatment of neurological disorders. The company draws on years of research in EEG analysis to develop products designed to improve the quality of patient care for those suffering from acute and chronic neurological disorders.

Optima’s initial product lines feature devices for bedside neurological status monitoring, including automated seizure detection and prediction. Epilepsy, affecting 1% of the population worldwide, leaves many patients searching for solutions better than currently available medical and surgical therapies to manage their symptoms.